Lupus is a chronic autoimmune disease that can cause widespread inflammation and affect many parts of the body, including the ...

Fate Therapeutics recently announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for the lupus treatment candidate FT819.

The CRISPR company is laying off about a third of its employees and stopping work on an experimental lupus treatment in a bid ...

A new study published in The Journal of the American Heart Association provides insights to improve cardiovascular disease ...

Join Drs Maureen McMahon and Michael Garshick as they discuss cardiovascular disease in patients with systemic lupus erythematosus, focusing on hidden risk and challenging clinical scenarios.

The U.S. Food and Drug Administration has granted regenerative medicine advanced therapy (RMAT) designation to Fate's FT819 ...

Persatuan SLE Malaysia (PSLEM) is committed to helping the Government set up a lupus registry to ensure proper allocation of resources to hospitals that treat lupus patients. Speaking at a charity ...

iPSC-derived CAR T-cell therapy currently in Phase 1 clinical development for the treatment of moderate to severe systemic lupus erythematosus or SLE, including lupus nephritis. Fate Therapeutics ...

Fate Therapeutics (NASDAQ:FATE) gets FDA RMAT designation for FT819, an experimental CAR T-cell therapy for lupus. Read more here.

Just 5% of pediatric providers feel highly confident in evaluating and managing neuropsychiatric SLE in youth.

“Sun exposure can trigger a lupus flare. Also, many of the medications used to treat lupus can make you more sensitive to the sun. That means using sunblock and covering up when out in sun,” Ghaw says ...